Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.38 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5876526 | 0.85 | NPSR1 (0.44) | NPSR1MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5876671 | 0.83 | NPSR1 (0.40) | NPSR1MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5878745 | 0.76 | KMT2A (0.39) | MAPTALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL5875992 | 0.74 | ALDH1A1 (0.41) | MAPTALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL5876313 | 0.73 | ALDH1A1 (0.41) | MAPTALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL5876614 | 0.70 | ALDH1A1 (0.39) | NPSR1MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5875943 | 0.70 | ALDH1A1 (0.38) | MAPTALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL5877161 | 0.70 | MAPT (0.40) | MAPTALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL5878190 | 0.69 | ALDH1A1 (0.39) | MAPTALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL5876976 | 0.68 | ALDH1A1 (0.36) | MAPTALDH1A1LMNASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119115-B2 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | AVENTIS PHARMA S.A. (FR) | 2006-10-10 | — | — | US | disclosed |
| US-20040162276-A1 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | AVENTIS PHARMA S.A. (FR) | 2004-08-19 | — | — | US | disclosed |
| EP-1414805-A1 | INDAZOLE OR INDOLE DERIVATIVES, THEIR USE IN HUMAN MEDICINE AND MORE PARTICULARLY IN CANCEROLOGY | Aventis Pharma S.A. (FR) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003011833-A1 | INDAZOLE OR INDOLE DERIVATIVES, THEIR USE IN HUMAN MEDICINE AND MORE PARTICULARLY IN CANCEROLOGY | AVENTIS PHARMA S.A. (FR) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162276-A1 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | IDO1, IDO2, INMT | NPSR1 797/4885MAPT 1879/4885ALDH1A1 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.